Ion Beam Applications SA (0GZK.L)

16.98 +0.38 (+2.29%) At close: 05:50PM BST

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve 1348
Belgium
32 1 047 58 11
https://www.iba-worldwide.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pierre Mottet	Chairman of The Board	52.5k	N/A	1962
Mr. Olivier Legrain	CEO, President, MD & Executive Director	880k	N/A	1968
Mr. Yves Jongen	Founder, Chief Research Officer, MD & Executive Director	576.92k	N/A	1947
Ms. Soumya Chandramouli	Chief Financial Officer	N/A	N/A	1979
Mr. Frederic Nolf	Chief Human Resources & Sustainability Officer	N/A	N/A	1973
Marc Van der Burght	Chief Operation Officer	N/A	N/A	N/A
Olivier Lechien	Corporate Communication Director	N/A	N/A	N/A
Thomas Canon	Sustainability Program Director	N/A	N/A	N/A
Bruno Scutnaire	President of IBA RadioPharma Solutions	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Corporate governance

Ion Beam Applications SA’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.